Physician profile
Basant Farghaly
NPI 1104945872
$1,733.61
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $571 · 2021: $556 · 2022: $89.83 · 2023: $219 · 2024: $94.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $313.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $613.00 | 2019-2023 | Wegovy |
| Lilly USA, LLC | $288.79 | 2019-2024 | Mounjaro, Zepbound |
| Abbvie INC. | $202.02 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $123.09 | 2021-2024 | Breztri, Farxiga |
| Allergan, INC. | $95.85 | 2019-2020 | |
| Amgen INC. | $83.32 | 2019-2024 | Otezla |
| Astellas Pharma US INC | $80.45 | 2020-2024 | Veozah |
| Merck Sharp & Dohme LLC | $77.23 | 2020-2023 | Verquvo |
| Ironwood Pharmaceuticals, INC | $38.13 | 2020-2021 | |
| Abbott Laboratories | $25.36 | 2023 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $20.48 | 2023 | Quviviq |
| Phadia US INC. | $19.69 | 2019 | |
| Boston Scientific Corporation | $19.25 | 2019 | |
| Zyla Life Sciences, INC. | $16.55 | 2019 | |
| Ibsa Pharma INC. | $15.58 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $14.82 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basant Farghaly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.